Targeting CK2 oncogenic pathway to overcome drug resistance in high-risk leukemia

Project: Research project

Description

SUMMARY The Ikaros (IKZF1) gene encodes a DNA-binding protein that functions as a tumor suppressor and a transcriptional regulator in leukemia. Deletion of one Ikaros allele results in the development of high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is resistant to chemotherapy and has a poor prognosis. Our recently published data show that CK2 (Casein Kinase II), an oncogenic kinase that is overexpressed in B-ALL, phosphorylates Ikaros, which reduces Ikaros DNA-binding affinity and abolishes its activity as a transcriptional regulator. Based on these findings we designed a novel B-ALL treatment strategy to restore Ikaros function by targeting CK2. The inhibition of CK2 with a specific inhibitor, CX-4945, as a single drug, restored Ikaros ability to regulate transcription in high-risk B-ALL with deletion of one Ikaros allele and showed therapeutic efficacy in a preclinical model of this disease. Our new preliminary data suggest that CK2 impairs the ability of Ikaros to repress transcription of genes essential to the folic acid metabolism pathway: MTHFD1 (methylene- tetrahydrofolate dehydrogenase NADP+ dependent 1), MTR (5-methyltetrahydrofolate-homocysteine methyl- transferase) and TYMS (Thymidylate Synthase), as well as the anti-apoptotic gene, BCL-XL. In leukemia, high expression of the folic acid pathway genes and BCL-XL are associated with increased resistance to methotrexate and doxorubicin treatment, respectively. Treatment with the CK2-specific inhibitor, CX-4945, restored Ikaros-mediated repression of the MTHFD1, MTR, TYMS and BCL-XL genes in primary high-risk B- ALL cells. In vitro treatment of high-risk B-ALL with CX-4945 in combination with methotrexate, or doxorubicin exhibits a strong synergistic cytotoxicity. We hypothesize that overexpression of CK2 in high-risk B-ALL impairs Ikaros ability to transcriptionally repress the folic acid pathway and Bcl-XL genes and that CK2 inhibition will restore Ikaros tumor suppressor activity as a transcriptional repressor of these genes in high-risk B-ALL cells resulting in increased sensitivity to methotrexate and doxorubicin treatment. We will test this hypothesis in vivo, using patient-derived xenografts (PDX) from pediatric patients with high-risk B- ALL in the following specific aims: In Aim 1, we will establish the therapeutic efficacy of combination treatment with the CK2 inhibitor (CX-4945) and the folic acid pathway inhibitor (methotrexate) in a preclinical model of high-risk B-ALL and determine the molecular mechanisms that restore Ikaros ability to repress folic acid pathway genes. In Aim 2, we will evaluate the in vivo efficacy of combination therapy with CX-4945 and doxorubicin and analyze the mechanism that restores Ikaros?mediated repression of BCL-XL in high-risk B-ALL. In Aim 3, we will identify the mechanisms through which high expression of CK2 regulates drug resistance and Ikaros tumor suppressor function in B-ALL. Results of the proposed project would establish the therapeutic efficacy of two novel combination treatments for high-risk B-ALL and provide mechanistic insights into the regulation of tumor suppression in pediatric high-risk B-ALL.
StatusActive
Effective start/end date6/15/175/31/22

Funding

  • National Institutes of Health: $353,876.00
  • National Institutes of Health: $353,876.00

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Resistance
Leukemia
B-Lymphocytes
Folic Acid
Methotrexate
Doxorubicin
Genes
Therapeutics
Thymidylate Synthase
Tetrahydrofolate Dehydrogenase
Homocysteine
Transferases
NADP
Neoplasms
Alleles
Pediatrics
Casein Kinase II
Essential Genes
DNA-Binding Proteins